Contemporary update on neoadjuvant therapy for bladder cancer

Nature Reviews Urology

Volumn 14, Issue 6, 2017, Pages 348-358

  Nguyen, Daniel P ^a   Thalmann, George N ^a  

^a UNIVERSITY OF BERN   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ATEZOLIZUMAB; BEVACIZUMAB; CANCER VACCINE; CISPLATIN; DOXORUBICIN; GEMCITABINE; IPILIMUMAB; METHOTREXATE; PEMBROLIZUMAB; SUNITINIB; VINBLASTINE; ANTINEOPLASTIC AGENT;

BLADDER CANCER; CANCER ADJUVANT THERAPY; CANCER GENETICS; CANCER IMMUNOTHERAPY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CREATININE CLEARANCE; CYSTECTOMY; DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION PROFILING; HEALTH CARE QUALITY; HEARING IMPAIRMENT; HEART FAILURE; HUMAN; LYMPH NODE DISSECTION; NEOADJUVANT CHEMOTHERAPY; NEUROPATHY; NEW YORK HEART ASSOCIATION CLASS; OVERALL SURVIVAL; PATIENT CARE; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; TRANSITIONAL CELL CARCINOMA; ADJUVANT CHEMOTHERAPY; BLADDER TUMOR; MORTALITY; NEOADJUVANT THERAPY; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CYSTECTOMY; HUMANS; NEOADJUVANT THERAPY; TREATMENT OUTCOME; URINARY BLADDER NEOPLASMS;

EID: 85015067173     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2017.30     Document Type: Review

References (143)

1. Ferlay, J. et al. GLOBOCAN 2012 v1.1, cancer incidence and mortality worldwide: IARC CancerBase No.11. Lyon, France: International Agency for Research on Cancer. http://globocan.iarc.fr (2014).
2. Furrer, M. A. et al. Patients with an orthotopic low pressure bladder substitute maintain good function in long term. J. Urol. 196, 1172-1180 (2016).
3. Madersbacher, S. et al. Radical cystectomy for bladder cancer today-a homogeneous series without neoadjuvant therapy. J. Clin. Oncol. 21, 690-696 (2003).
4. Stein, J. P. et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J. Clin. Oncol. 19, 666-675 (2001).
5. Hautmann, R. E., De Petriconi, R. C., Pfeiffer, C. & Volkmer, B. G. Radical cystectomy for urothelial carcinoma of the bladder without neoadjuvant or adjuvant therapy: long-term results in 1100 patients. Eur. Urol. 61, 1039-1047 (2012).
6. Dotan, Z. A. et al. Positive surgical margins in soft tissue following radical cystectomy for bladder cancer and cancer specific survival. J. Urol. 178, 2308-2312 (2007).
7. Yafi, F. A. et al. Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience. BJU Int. 110, 1317-1323 (2012).
8. Zehnder, P. et al. Unaltered oncological outcomes of radical cystectomy with extended lymphadenectomy over three decades. BJU Int. 112, E51-E58 (2013).
9. Reardon, Z. D. et al. Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: A sign of changing tides. Eur. Urol. 67, 165-170 (2015).
10. Hermans, T. J. N. et al. Perioperative treatment and radical cystectomy for bladder cancer-a population based trend analysis of 10,338 patients in the Netherlands. Eur. J. Cancer 54, 18-26 (2016).
11. Clark, P. E. et al. NCCN Guidelines Insights: Bladder Cancer, Version 2.2016. J. Natl Compr. Canc. Netw. 14, 1213-1224 (2016).
12. Logothetis, C. J. et al. A prospective randomized trial comparing MVAC and CISCA chemotherapy for patients with metastatic urothelial tumors. J. Clin. Oncol. 8, 1050-1055 (1990).
13. Loehrer, P. et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: A cooperative study. J. Clin. Oncol. 10, 1066-1073 (1992).
14. Fleischmann, A., Thalmann, G. N., Perren, A. & Seiler, R. Tumor regression grade of urothelial bladder cancer after neoadjuvant chemotherapy: A novel and successful strategy to predict survival. Am. J. Surg. Pathol. 38, 325-332 (2014).
15. Bassi, P. et al. Neoadjuvant M-VAC chemotherapy of invasive bladder cancer: results of a multicenter phase III trial. J. Urol. 161 (Suppl.), 264 (1999).
16. Cannobio, L. et al. A randomized study between neo-adjuvant chemoradiotherapy (CT-RT) before radical cystectomy and cystectomy alone in bladder cancer. A 6-year follow-up. Proc. Am. Soc. Clin. Oncol. 14, 245 (1995).
17. GISTV (Italian Bladder Cancer Study Group). Neoadjuvant treatment for locally advanced bladder cancer: A randomized prospective trial. J. Chemother. 8 (Suppl.), 345-346 (1996).
18. [No authors listed.] Neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: A randomised controlled trial. International collaboration of trialists. Lancet 354, 533-540 (1999).
19. Griffiths, G. et al. International phase III trial assessing neoadjuvant cisplatin, methotrexate, and vinblastine chemotherapy for muscle-invasive bladder cancer: long-term results of the BA06 30894 trial. J. Clin. Oncol. 29, 2171-2177 (2011).
20. Sherif, A. et al. Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: A combined analysis of two Nordic studies. Eur. Urol. 45, 297-303 (2004).
21. Grossman, H. B. et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N. Engl. J. Med. 349, 859-866 (2003).
22. Winquist, E., Kirchner, T. S., Segal, R., Chin, J. & Lukka, H. Neoadjuvant chemotherapy for transitional cell carcinoma of the bladder: A systematic review and meta-analysis. J. Urol. 171, 561-569 (2004).
23. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and meta-analysis of individual patient data. Eur. Urol. 48, 202-206 (2005).
24. Rosenblatt, R. et al. Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur. Urol. 61, 1229-1238 (2012).
25. Kitamura, H. et al. Randomised phase III study of neoadjuvant chemotherapy with methotrexate, doxorubicin, vinblastine and cisplatin followed by radical cystectomy compared with radical cystectomy alone for muscle-invasive bladder cancer: Japan Clinical Oncology Group Study. Ann. Oncol. 25, 1192-1198 (2014).
26. Von Der Maase, H. et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J. Clin. Oncol. 23, 4602-4608 (2005).
27. Zargar, H. et al. Final pathologic stage after neoadjuvant chemotherapy and radical cystectomy for bladder cancer: does pT0 predict better survival than pTa/Tis/T1 J. Urol. 195, 886-893 (2015).
28. Zargar, H. et al. Multicenter assessment of neoadjuvant chemotherapy for muscle-invasive bladder cancer. Eur. Urol. 67, 241-249 (2015).
29. Lee, F. C. et al. Pathologic response rates of gemcitabine/cisplatin versus methotrexate/vinblastine/adriamycin/cisplatin neoadjuvant chemotherapy for muscle invasive urothelial bladder cancer. Adv. Urol. 2013, 317190 (2013).
30. Fairey, A. S. et al. Neoadjuvant chemotherapy with gemcitabine/cisplatin versus methotrexate/vinblastine/doxorubicin/cisplatin for muscle-invasive urothelial carcinoma of the bladder: A retrospective analysis from the University of Southern California. Urol. Oncol. 31, 1737-1743 (2013).
31. Dash, A. et al. A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: A retrospective experience. Cancer 113, 2471-2477 (2008).
32. Galsky, M. D. et al. Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer 121, 2586-2593 (2015).
33. Choueiri, T. K. et al. Neoadjuvant dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin with pegfilgrastim support in muscle-invasive urothelial cancer: pathologic, radiologic, and biomarker correlates. J. Clin. Oncol. 32, 1889-1894 (2014).
34. Plimack, E. R. et al. Accelerated methotrexate, vinblastine, doxorubicin, and cisplatin is safe, effective, and efficient neoadjuvant treatment for muscle-invasive bladder cancer: results of a multicenter phase II study with molecular correlates of response and toxicity. J. Clin. Oncol. 32, 1895-1901 (2014).
35. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01812369 (2016).
36. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01611662 (2015).
37. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT01589094 (2016).
38. Plimack, E. R. et al. Neoadjuvant dose-dense gemcitabine and cisplatin in patients with muscle-invasive bladder cancer (MIBC): final results of a multicenter phase II study [abstract]. J. Clin. Oncol. 32 (Suppl.), 4513 (2014).
39. Herr, H. W. et al. Surgical factors influence bladder cancer outcomes: A cooperative group report. J. Clin. Oncol. 22, 2781-2789 (2004).
40. Johnson, D. C. et al. Neoadjuvant chemotherapy for bladder cancer does not increase risk of perioperative morbidity. BJU Int. 114, 221-222 (2014).
41. Thompson, R. H. et al. Eligibility for neoadjuvant/adjuvant cisplatin-based chemotherapy among radical cystectomy patients. BJU Int. 113, 17-21 (2014).
42. Canter, D. et al. Baseline renal function status limits patient eligibility to receive perioperative chemotherapy for invasive bladder cancer and is minimally affected by radical cystectomy. Urology 77, 160-165 (2011).
43. Dash, A. et al. Impact of renal impairment on eligibility for adjuvant cisplatin-based chemotherapy in patients with urothelial carcinoma of the bladder. Cancer 107, 506-513 (2006).
44. Galsky, M. D. et al. A consensus definition of patients with metastatic urothelial carcinoma who are unfit for cisplatin-based chemotherapy. Lancet Oncol. 12, 211-214 (2011).
45. Galsky, M. D. et al. Comparative effectiveness of cisplatin-based and carboplatin-based chemotherapy for treatment of advanced urothelial carcinoma. Ann. Oncol. 23, 406-410 (2012).
46. Witjes, J. A. et al. EAU guidelines on muscle-invasive and metastatic bladder cancer: summary of the 2013 guidelines. Eur. Urol. 65, 778-792 (2014).
47. Apolo, A. B., Grossman, H. B., Bajorin, D., Steinberg, G. & Kamat, A. M. Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: summary of session at the Society of Urologic Oncology annual meeting. Urol. Oncol. 30, 772-780 (2012).
48. Sternberg, C. N. et al. Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours. Eur. J. Cancer 42, 50-54 (2006).
49. Petrelli, F. et al. Correlation of pathologic complete response with survival after neoadjuvant chemotherapy in bladder cancer treated with cystectomy: A meta-analysis. Eur. Urol. 65, 350-357 (2014).
50. Sonpavde, G. et al. Quality of pathologic response and surgery correlate with survival for patients with completely resected bladder cancer after neoadjuvant chemotherapy. Cancer 115, 4104-4109 (2009).
51. Milowsky, M. I. et al. Guideline on muscle-invasive and metastatic bladder cancer (European Association of Urology guideline): American Society of Clinical Oncology clinical practice guideline endorsement. J. Clin. Oncol. 34, 1945-1952 (2016).
52. Lee, C. T. et al. Cystectomy delay more than 3 months from initial bladder cancer diagnosis results in decreased disease specific and overall survival. J. Urol. 175, 1262-1267 (2006).
53. Sánchez-Ortiz, R. F. et al. An interval longer than 12 weeks between the diagnosis of muscle invasion and cystectomy is associated with worse outcome in bladder carcinoma. J. Urol. 169, 110-115 (2003).
54. Nielsen, M. E. et al. A delay in radical cystectomy of 3 months is not associated with a worse clinical outcome. BJU Int. 100, 1015-1020 (2007).
55. Haas, C. R. et al. The timing of radical cystectomy for bacillus Calmette-Guérin failure: comparison of outcomes and risk factors for prognosis. J. Urol. 195, 1704-1709 (2016).
56. Leow, J. J. et al. Adjuvant chemotherapy for invasive bladder cancer: A 2013 updated systematic review and meta-analysis of randomized trials. Eur. Urol. 66, 42-54 (2014).
57. Galsky, M. D. et al. Effectiveness of adjuvant chemotherapy for locally advanced bladder cancer. J. Clin. Oncol. 34, 825-832 (2016).
58. Svatek, R. S. et al. The effectiveness of off-protocol adjuvant chemotherapy for patients with urothelial carcinoma of the urinary bladder. Clin. Cancer Res. 16, 4461-4467 (2010).
59. Dorff, T. B. et al. Adjuvant chemotherapy for locally advanced urothelial carcinoma: An overview of the USC experience. World J. Urol. 27, 39-44 (2009).
60. Donat, S. M. et al. Potential impact of postoperative early complications on the timing of adjuvant chemotherapy in patients undergoing radical aystectomy: A high-volume tertiary cancer center experience. Eur. Urol. 55, 177-186 (2009).
61. Millikan, R. et al. Integrated therapy for locally advanced bladder cancer: final report of a randomized trial of cystectomy plus preoperative and postoperative M-VAC. J. Clin. Oncol. 19, 4005-4013 (2001).
62. Wosnitzer, M. S. et al. A comparison of the outcomes of neoadjuvant and adjuvant chemotherapy for clinical T2-T4aN0-N2M0 bladder cancer. Cancer 118, 358-364 (2012).
63. Culp, S. H. et al. Refining patient selection for neoadjuvant chemotherapy before radical cystectomy. J. Urol. 191, 40-47 (2014).
64. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: A systematic review and meta-analysis. Lancet 361, 1927-1934 (2003).
65. Svatek, R. S. et al. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int. 107, 898-904 (2011).
66. Shariat, S. F. et al. Discrepancy between clinical and pathologic stage: impact on prognosis after radical cystectomy. Eur. Urol. 51, 137-151 (2007).
67. Ficarra, V. et al. Correlation between clinical and pathological staging in a series of radical cystectomies for bladder carcinoma. BJU Int. 95, 786-790 (2005).
68. Hollenbeck, B. K., Miller, D. C., Dunn, R. L., Montie, J. E. & Wei, J. T. The effects of stage divergence on survival after radical cystectomy for urothelial cancer. Urol. Oncol. 23, 77-81 (2005).
69. Scosyrev, E. et al. Do mixed histological features affect survival benefit from neoadjuvant platinum-based locally advanced bladder cancer A secondary analysis of Southwest Oncology Group-Directed Intergroup Study (S8710). BJU Int. 108, 693-699 (2010).
70. Zargar-Shoshtari, K. et al. Clinical outcomes after neoadjuvant chemotherapy and radical cystectomy in the presence of urothelial carcinoma of the bladder with squamous or glandular differentiation. Clin. Genitourin. Cancer 14, 82-88 (2016).
71. Kastritis, E. et al. The outcome of patients with advanced pure squamous or mixed squamous and transitional urothelial carcinomas following platinum-based chemotherapy. Anticancer Res. 26, 3865-3869 (2006).
72. Lynch, S. P. et al. Neoadjuvant chemotherapy in small cell urothelial cancer improves pathologic downstaging and long-term outcomes: results from a retrospective study at the MD Anderson Cancer Center. Eur. Urol. 64, 307-313 (2013).
73. Ghoneim, I. A. et al. Neoadjuvant systemic therapy or early cystectomy Single-center analysis of outcomes after therapy for patients with clinically localized micropapillary urothelial carcinoma of the bladder. Urology 77, 867-870 (2011).
74. Kamat, A. M. et al. Micropapillary bladder cancer: A review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer 110, 62-67 (2007).
75. Meeks, J. J. et al. Pathological response to neoadjuvant chemotherapy for muscle-invasive micropapillary bladder cancer. BJU Int. 111, 325-330 (2013).
76. Guo, C. C. et al. Bladder cancer gene expression profile of the clinically aggressive micropapillary variant of bladder cancer. Eur. Urol. 70, 611-620 (2016).
77. Willis, D. L. et al. Micropapillary bladder cancer: current treatment patterns and review of the literature. Urol. Oncol. 32, 826-832 (2014).
78. Black, P. C. et al. Variant histology in bladder cancer-experience in 1,246 patients undergoing cystectomy. J. Urol. 177, 502 (2007).
79. Chaudhary, U. B. et al. Phase II trial of neoadjuvant cisplatin, gemcitabine, and bevacizumab followed by radical cystectomy in patients with muscle-invasive transitional cell carcinoma of the bladder [abstract]. J. Clin. Oncol. 29 (Suppl. 7), 276 (2011).
80. McConkey, D. J. et al. A prognostic gene expression signature in the molecular classification of chemotherapy-naive urothelial cancer is predictive of clinical outcomes from neoadjuvant chemotherapy: A phase 2 trial of dose-dense methotrexate, vinblastine, doxorubicin, and cisplatine with bevacizumab in urothelial cancer. Eur. Urol. 69, 855-862 (2015).
81. Balar, A. V. et al. Phase II trial of neoadjuvant gemcitabine and cisplatin with sunitinib in patients with muscle-invasive bladder cancer [abstract]. J. Clin. Oncol. 30 (Suppl.), 4581 (2012).
82. Pruthi, R. S. et al. A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer pathological results. BJU Int. 106, 349-356 (2010).
83. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00380029 (2016).
84. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02169284 (2017).
85. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT00749892 (2016).
86. Hahn, N. M. et al. Neoadjuvant dasatinib for muscle-invasive bladder cancer with tissue analysis of biologic activity. Urol. Oncol. 34, 4.e11-4.e17 (2016).
87. Sonpavde, G., Jones, B. S., Bellmunt, J., Choueiri, T. K. & Sternberg, C. N. Future directions and targeted therapies in bladder cancer. Hematol. Oncol. Clin. North Am. 29, 361-376 (2014).
88. Kurtoglu, M. et al. Elevating the horizon: emerging molecular and genomic targets in the treatment of advanced urothelial carcinoma. Clin. Genitourin. Cancer 13, 410-420 (2015).
89. Bajorin, D. F. et al. Preliminary product parameter and safety results from NeuACT, a phase 2 randomized, open-label trial of DN24-02 in patients with surgically resected HER2+ urothelial cancer at high risk for recurrence [abstract]. J. Clin. Oncol. 32 (Suppl.), 4541 (2014).
90. Fleischmann, A., Rotzer, D., Seiler, R., Studer, U. E. & Thalmann, G. N. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. Eur. Urol. 60, 350-357 (2011).
91. Tschui, J. et al. Morphological and molecular characteristics of HER2 amplified urothelial bladder cancer. Virchows Arch. 466, 703-710 (2015).
92. Bajorin, D. F. et al. Phase 2 trial results of DN24-02, a HER2-targeted autologous cellular immunotherapy in HER2+ urothelial cancer patients [abstract]. J. Clin. Oncol. 34 (Suppl.), 4513 (2016).
93. Pardoll, D. M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252-264 (2012).
94. Carthon, B. C. et al. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin. Cancer. Res. 16, 2861-2871 (2010).
95. Chen, D. S., Irving, B. A. & Hodi, F. S. Molecular pathways: next-generation immunotherapy-inhibiting programmed death-ligand 1 and programmed death-1. Clin. Cancer Res. 18, 6580-6587 (2012).
96. Inman, B. A. et al. PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: Associations with localized stage progression. Cancer 109, 1499-1505 (2007).
97. Nakanishi, J. et al. Overexpression of B7-H1 (PD-L1) significantly associates with tumor grade and postoperative prognosis in human urothelial cancers. Cancer Immunol. Immunother. 56, 1173-1182 (2007).
98. Grivas, P. et al. PD1, PDL1, PDL2 tumor tissue expression as predictors of response to neoadjuvant chemotherapy and outcome in bladder cancer [abstract]. J. Clin. Oncol. 34 (Suppl.), e16023 (2016).
99. Powles, T. et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558-562 (2014).
100. Petrylak, D. P. et al. A phase Ia study of MPDL3280A (anti-PDL1): updated response and survival data in urothelial bladder cancer [abstract]. J. Clin. Oncol. 33 (Suppl.), 4501 (2015).
101. Rosenberg, J. E. et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: A single-arm, multicentre, phase 2 trial. Lancet 387, 1909-1920 (2016).
102. Balar, A. V. et al. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: A single arm, multicentre, phase 2 trial. Lancet 389, 67-76 (2017).
103. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02450331 (2016).
104. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02302807 (2016).
105. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02451423 (2016).
106. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02662309 (2016).
107. Plimack, E. R. et al. Safety and activity of pembrolizumab in patients with locally advanced or metastatic urothelial cancer (KEYNOTE-012): A non-randomised, open-label, phase 1b study. Lancet Oncol. 18, 212-220 (2017).
108. Bajorin, D. F. et al. KEYNOTE-052: phase 2 study of pembrolizumab (MK-3475) as first-line therapy for patients with unresectable or metastatic urothelial cancer ineligible for cisplatin-based therapy [abstract]. J. Clin. Oncol. 33 (Suppl.), TPS4572 (2015).
109. Bellmunt, J. et al. KEYNOTE-045: randomized phase 3 trial of pembrolizumab (MK-3475) versus paclitaxel, docetaxel, or vinflunine for previously treated metastatic urothelial cancer [abstract]. J. Clin. Oncol. 33 (Suppl.), TPS4571 (2015).
110. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02500121 (2016).
111. Sharma, P. et al. Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer: results from the phase I/II CheckMate 032 study [abstract]. J. Clin. Oncol. 34 (Suppl.), 4501 (2016).
112. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02632409 (2017).
113. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02516241 (2017).
114. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02603432 (2017).
115. Cook, A. M., Lesterhuis, W. J., Nowak, A. K. & Lake, R. A. Chemotherapy and immunotherapy: mapping the road ahead. Curr. Opin. Immunol. 39, 23-29 (2016).
116. Emens, L. A. & Middleton, G. The interplay of immunotherapy and chemotherapy: harnessing potential synergies. Cancer Immunol. Res. 3, 436-443 (2015).
117. Spigel, D. R. & Socinski, M. A. Rationale for chemotherapy, immunotherapy, and checkpoint blockade in SCLC: beyond traditional treatment approaches. J. Thorac. Oncol. 8, 587-598 (2013).
118. Prieto, P. A., Reuben, A., Cooper, Z. A. & Wargo, J. A. Targeted therapies combined with immune checkpoint therapy. Cancer J. 22, 138-146 (2016).
119. Galsky, M. D. et al. Phase II trial of gemcitabine + cisplatin + ipilimumab in patients with metastatic urothelial cancer [abstract]. J. Clin. Oncol. 34 (Suppl.), 357 (2016).
120. Hoimes, C. J. et al. HCRN GU14-188: neoadjuvant pembrolizumab and gemcitabine with or without cisplatin in muscle invasive urothelial cancer [abstract]. J. Clin. Oncol. 34 (Suppl.), TPS4578 (2016).
121. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02690558 (2016).
122. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/nct02437370 (2016).
123. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02807636 (2017).
124. Takata, R. et al. Predicting response to methotrexate, vinblastine, doxorubicin, and cisplatin neoadjuvant chemotherapy for bladder cancers through genome-wide gene expression profiling. Clin. Cancer. Res. 11, 2625-2636 (2007).
125. Weinstein, J. N. et al. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 507, 315-322 (2014).
126. Van Allen, E. M. et al. Somatic ERCC2 mutations correlate with cisplatin sensitivity in muscle-invasive urothelial carcinoma. Cancer Discov. 4, 1140-1153 (2014).
127. Plimack, E. R. et al. Defects in DNA repair genes predict response to neoadjuvant cisplatin-based chemotherapy in muscle-invasive bladder cancer. Eur. Urol. 68, 959-967 (2015).
128. Groenendijk, F. H. et al. ERBB2 mutations characterize a subgroup of muscle-invasive bladder cancers with excellent response to neoadjuvant chemotherapy. Eur. Urol. 69, 384-388 (2015).
129. Guo, G. et al. Whole-genome and whole-exome sequencing of bladder cancer identifies frequent alterations in genes involved in sister chromatid cohesion and segregation. Nat. Genet. 45, 1459-1463 (2013).
130. Iyer, G. et al. Prevalence and co-occurrence of actionable genomic alterations in high-grade bladder cancer. J. Clin. Oncol. 31, 3133-3140 (2013).
131. Lee, J. K. et al. A strategy for predicting the chemosensitivity of human cancers and its application to drug discovery. Proc. Natl Acad. Sci. USA 104, 13086-13091 (2008).
132. US National Library of Medicine. ClinicalTrials.gov https://clinicaltrials.gov/ct2/show/NCT02177695 (2017).
133. Choi, W. et al. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell 25, 152-165 (2014).
134. Damrauer, J. S. et al. Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. Proc. Natl Acad. Sci. USA 111, 3110-3115 (2014).
135. Sjödahl, G. et al. A molecular taxonomy for urothelial carcinoma. Clin. Cancer Res. 18, 3377-3386 (2012).
136. McConkey, D. J., Choi, W. & Dinney, C. P. Genetic subtypes of invasive bladder cancer. Curr. Opin. Urol. 25, 449-458 (2015).
137. Aine, M., Eriksson, P., Liedberg, F., Sjödahl, G. & Höglund, M. Biological determinants of bladder cancer gene expression subtypes. Sci. Rep. 5, 10957 (2015).
138. Abdollah, F. et al. Stage-specific impact of pelvic lymph node dissection on survival in patients with non-metastatic bladder cancer treated with radical cystectomy. BJU Int. 109, 1147-1154 (2012).
139. Dhar, N. B. et al. Outcome after radical cystectomy with limited or extended pelvic lymph node dissection. J. Urol. 179, 873-978 (2008).
140. Herr, H. W. Impact of the number of lymph nodes retrieved on outcome in patients with muscle invasive bladder cancer. J. Urol. 167, 1295-1298 (2002).
141. Weingärtner, K. et al. Anatomical basis for pelvic lymphadenectomy in prostate cancer: results of an autopsy study and implications for the clinic. J. Urol. 156, 1969-1971 (1996).
142. Nguyen, L. T. & Ohashi, P. S. Clinical blockade of PD1 and LAG3 - potential mechanisms of action. Nat. Rev. Immunol. 15, 45-56 (2015).
143. Choi, W. et al. Intrinsic basal and luminal subtypes of muscle-invasive bladder cancer. Nat. Rev. Urol. 11, 400-410 (2014).